SCHEDULE 13G/A

LYELL IMMUNOPHARMA INC

Common Stock, par value $0.0001 · CUSIP: 55083R104

Event date: 2025-03-31

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares

Unavailable

Percent of class

Unavailable

• Foresite Capital Fund IV, L.P.

  Shares: 16,007,999.00 · Class: 5.4%

• Foresite Capital Management IV, LLC

  Shares: 16,007,999.00 · Class: 5.4%

• Foresite Capital Fund V, L.P.

  Shares: 8,133,047.00 · Class: 2.8%

• Foresite Capital Management V, LLC

  Shares: 8,133,047.00 · Class: 2.8%

• Foresite Capital Opportunity Fund V, L.P.

  Shares: 3,020,846.00 · Class: 1.0%

• Foresite Capital Opportunity Management V, LLC

  Shares: 3,020,846.00 · Class: 1.0%

• James B. Tananbaum

  Shares: 27,161,892.00 · Class: 9.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.